CDK4 and adenocarcinoma: For non-intestinal BG adenocarcinoma, a whole-genome case revealed somatic PTEN loss (exons 2–5) together with CCND1 amplification; these findings supported everolimus (mTOR inhibitor) followed by palbociclib (CDK4/6 inhibitor) with radiologic responses under compassionate use [106].